LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Sanofi

Suletud

50.48 1.96

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

49.14

Max

50.55

Põhinäitajad

By Trading Economics

Sissetulek

1.4B

1.9B

Müük

3B

11B

P/E

Sektori keskmine

17.382

51.198

Aktsiakasum

1.022

Dividenditootlus

4.5

Kasumimarginaal

17.65

Töötajad

82,878

EBITDA

2.2B

2.8B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+23.24% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.50%

2.40%

Turustatistika

By TradingEconomics

Turukapital

-17B

121B

Eelmine avamishind

48.52

Eelmine sulgemishind

50.48

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Sanofi Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2025, 16:05 UTC

Suurimad hinnamuutused turgudel

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2. juuni 2025, 09:17 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2. juuni 2025, 05:31 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22. mai 2025, 12:02 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22. mai 2025, 00:06 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Vigil Neuroscience for About $470 Million

2. juuni 2025, 13:50 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. juuni 2025, 12:33 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2. juuni 2025, 10:50 UTC

Omandamised, ülevõtmised, äriostud

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. juuni 2025, 10:05 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2. juuni 2025, 05:06 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2. juuni 2025, 05:06 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2. juuni 2025, 05:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2. juuni 2025, 05:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2. juuni 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2. juuni 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2. juuni 2025, 05:03 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Blueprint Medicines Corporation

2. juuni 2025, 05:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Blueprint Medicines Corporation

30. mai 2025, 08:58 UTC

Kuumad aktsiad

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30. mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27. mai 2025, 05:03 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27. mai 2025, 05:00 UTC

Omandamised, ülevõtmised, äriostud

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21. mai 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21. mai 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21. mai 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21. mai 2025, 23:23 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21. mai 2025, 23:22 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21. mai 2025, 23:20 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21. mai 2025, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

12. mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8. mai 2025, 17:55 UTC

Tulu

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Sanofi Prognoos

Hinnasiht

By TipRanks

23.24% tõus

12 kuu keskmine prognoos

Keskmine 62.2 USD  23.24%

Kõrge 67 USD

Madal 56 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sanofi 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

2

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

51.665 / 52.38Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.